When talking with friends and acquaintances about how I think leronlimab is interesting, I'm learning to keep my conversations to the trials data, their announcements, and how things take time. Even then, these topics have grown into much more than most people think possible for one drug and it is often VERY hard for them to get past that. Sometimes I just talk about one disease to keep it simple.

I like conversations that point to a potential positive impact on the world. Whether acquaintances are inclined to learn more on their own is up to them.

So I'm saying that sometimes investors (myself) who follow companies deeply have a hard time effectively talking to people who haven't heard of the drug. We know so many details, yet the listener may not have the temperament of an investor who might "drink from a firehose". I'm trying to improve.

I thought the CYDY management conference call was full of good updates.

JMO